As part of the Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) announced a task order with Emergent BioSolutions to advance manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics.
The task order is worth approximately $628 million and falls under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of HHS’s Office of the Assistant Secretary for Preparedness and Response.
Under the task order, Emergent will commit contract development and manufacturing organization (CDMO) drug substance and drug product manufacturing capacity valued at approximately $542.75 million for production of COVID-19 vaccine candidates through 2021, in addition to an investment of approximately $85.5 million for the rapid expansion of Emergent’s viral and non-viral CDMO fill/finish capacity for vaccine and therapeutic manufacturing.
Before this task order announcement, Emergent had begun collaborating on development and manufacturing with Johnson & Johnson, Novavax, and Vaxart on their COVID-19 vaccine candidates. Johnson & Johnson’s candidate has received BARDA support. BARDA has invested since 2012 to expand domestic manufacturing capabilities in the United States, including creating three Centers for Innovation in Advanced Development and Manufacturing; one of the centers is managed by Emergent and becomes the first to be deployed for the Operation Warp Speed effort.
